Errata to: Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines (14, 17–18, (1971–1976), 10.1002/pmic.201300448);Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines

Proteomics

Volumn 14, Issue 17-18, 2014, Pages 1971-1976

  Aasebø, Elise ^a   Vaudel, Marc ^a   Mjaavatten, Olav ^a   Gausdal, Gro ^a   van der Burgh, Arthur ^a   Gjertsen, Bjørn Tore ^a   Døskeland, Stein Ove ^a   Bruserud, Øystein ^a   Berven, Frode S ^a   Selheim, Frode ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Acute myeloid leukemia; Biomedicine; Cell lines; Super SILAC

Indexed keywords

PROTEIN; PROTEOME; TUMOR MARKER; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INHIBITOR OF NUCLEAR FACTOR KAPPA B KINASE SUBUNIT BETA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; STAT3 PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CELL CULTURE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LEUKEMIA CELL LINE; MOLECULAR GENETICS; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RISK FACTOR; SUPER SILAC; ACUTE MYELOBLASTIC LEUKEMIA; CHEMISTRY; MASS SPECTROMETRY; METABOLISM; PROCEDURES; TUMOR CELL LINE; ACUTE MYELOID LEUKEMIA; CELL FRACTIONATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVE SITE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; STANDARD; SUPER SILAC PROCEDURE;

CELL LINE, TUMOR; HUMANS; ISOTOPE LABELING; LEUKEMIA, MYELOID, ACUTE; MASS SPECTROMETRY; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908619731     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201670143b     Document Type: Erratum

References (26)

1. O'Donnell, M., Risk stratification and emerging treatment strategies in acute myeloid leukemia. J. Natl. Compr. Canc. Netw. 2013, 11, 667-669.
2. Kumar, C., Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer 2011, 2, 95-107.
3. Döhner, H., Estey, E., Amadori, S., Appelbaum, F. et al., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115, 453-474.
4. Estey, E., Acute myeloid leukemia: 2013 update on risk-stratification and management. Am. J. Hematol. 2013, 88, 318-327.
5. Ong, S.-E., Mann, M., Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 2005, 1, 252-262.
6. Aebersold, R., Mann, M., Mass spectrometry-based proteomics. Nature 2003, 422, 198-207.
7. Foss, E. J., Radulovic, D., Stirewalt, D. L., Radich, J. et al., Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets. J. Proteome Res. 2012, 11, 5005-5010.
8. Wiśniewski, J., Ostasiewicz, P., Duś, K., Zielińska, D. et al., Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma. Mol. Syst. Biol. 2012, 8, 611.
9. Hjelle, S., Forthun, R., Haaland, I., Reikvam, H. et al., Clinical proteomics of myeloid leukemia. Genome Med. 2010, 2, 41.
10. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J., Mann, M., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 2010, 7, 383-385.
11. Matsuo, Y., MacLeod, R. A., Uphoff, C. C., Drexler, H. G. et al., Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 1997, 11, 1469-1477.
12. Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P. et al., NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991, 77, 1080-1086.
13. Lange, B., Valtieri, M., Santoli, D., Caracciolo, D. et al., Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 1987, 70, 192-199.
14. Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y. et al., Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int. J. cancer 1980, 26, 171-176.
15. Quentmeier, H., Martelli, M., Dirks, W., Bolli, N. et al., Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005, 19, 1760-1767.
16. Patel, J., Gönen, M., Figueroa, M., Fernandez, H. et al., Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. New Engl. J. Med. 2012, 366, 1079-1089.
17. Cancer Genome Atlas Research, N., Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl. J. Med. 2013, 368, 2059-2074.
18. Quentmeier, H., Reinhardt, J., Zaborski, M., Drexler, H. G., FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003, 17, 120-124.
19. Falini, B., Nicoletti, I., Martelli, M., Mecucci, C., Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109, 874-885.
20. Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28, 27-30.
21. Spiekermann, K., Bagrintseva, K., Schwab, R., Schmieja, K., Hiddemann, W., Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. Clin. Cancer Res. 2003, 9, 2140-2150.
22. Warsch, W., Kollmann, K., Eckelhart, E., Fajmann, S. et al., High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011, 117, 3409-3420.
23. Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A. et al., ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 2014, 32, 223-226.
24. Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A. et al., The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41, D1063-D1069.
25. Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G. et al., Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Brit. J. Haematol. 1976, 33, 451-458.
26. Cox, J., Mann, M., MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26, 1367-1372.